ArticleFrontiers in oncology2026
Successful conversion therapy of advanced gallbladder carcinoma by chemotherapy combined with immunotherapy: two case reports.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Gallbladder cancer (GBC) is a highly aggressive malignancy of the biliary system and is frequently diagnosed at an advanced stage upon initial presentation. Nonetheless, the introduction of conversion therapy has allowed certain initially inoperable cases of GBC to become candidates for radical resection after comprehensive modalities, including chemotherapy, immunotherapy, and radiotherapy. In the current retrospective analysis, we present two patients with initially unresectable GBC treated at Xiangyang Central Hospital, affiliated with Hubei University of Arts and Science. After receiving a combination of chemotherapy and immunotherapy, substantial tumor regression was observed at both primary and metastatic sites, achieving partial remission according to the Response Evaluation Criteria in Solid Tumors (RECIST). Conversion therapy proved effective, enabling both patients to undergo successful radical resections. Following surgery, the original therapeutic regimen was continued until completion of five cycles. Follow-up extended through November 2025, with no evidence of tumor recurrence observed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.